Hypertension management in elderly with severe intracerebral hemorrhage
Jingjing Zhao,Fang Yuan,Feng Fu,Yi Liu,Changhu Xue,Kangjun Wang,Xiangjun Yuan,Dingan Li,Qiuwu Liu,Wei Zhang,Yi Jia,Jianbo He,Jun Zhou,Xiaocheng Wang,Hua Lv,Kang Huo,Zhuanhui Li,Bei Zhang,Chengkai Wang,Xiaomu Wang,Hongzeng Li,Fang Yang,Wen Jiang,the CHASE Study Group,
DOI: https://doi.org/10.1002/acn3.51455
IF: 5.43
2021-09-29
Annals of Clinical and Translational Neurology
Abstract:ObjectiveTo explore the effect of individualized blood pressure (BP)-lowering treatment on the outcomes of elderly patients with severe intracerebral hemorrhage (ICH). MethodsWe performed an exploratory analysis of Controlling Hypertension After Severe Cerebrovascular Event (CHASE) trial, which was a multicenter, randomized, controlled clinical trial. Patients with severe ischemic or hemorrhagic stroke (defined as GCS ≤ 12 or NIHSS ≥ 11) were randomized into individualized versus standard BP-lowering treatment in CHASE trial. In this exploratory analysis, patients with severe ICH were included. The primary outcome was the percentage of patients with 90-day functional independence defined as modified Rankin Scale (mRS) ≤2. ResultsWe included 242 patients with severe ICH in the present analysis, consisting of 142 patients aged <65 years and 100 patients aged ≥65 years. There were significant differences between patients aged ≥65 years and <65 years in the proportion of functional independence (47.9% vs. 15.0%, P < 0.001) and good outcome (73.9% vs. 50.0%, P < 0.001) at day 90. In patients aged ≥65 years, the adjusted individualized BP-lowering treatment had an unequivocal effect on the functional independence at day 90 (21.6% vs. 8.2%, odds ratio [OR]: 4.309, 95% confidence interval [CI]: 1.040-17.859, P = 0.044) and improved the neurological deficits at discharge (∆ NIHSS ≥ 4: 64.7% vs. 34.7%, OR: 4.300, 95% CI: 1.599-11.563, P = 0.004). InterpretationCompared with the younger counterparts, the elderly patients (≥65 years) with acute severe ICH might benefit more from individualized BP-lowering treatment.
neurosciences,clinical neurology